BrightSpring Health Services Inc. Common Stock

BTSG | NASDAQ

Price Alert Chart Builder DCF Calculator

$56.78

+$0.18 (+0.32%)

At close: Sep 18, 2026, 4:00 PM ET

$57

+$0.22 (+0.39%)

Pre-market: Sep 21, 2026, 8:46 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.32%

(1D)

Rating

Updated: Aug 28, 2026

50.8

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $11.14B

1D Range

55.64 57.51

52W Range

26.28 73.75

Valuation (TTM)

PE 42.37

PB 5.44

EV/EBITDA 20.60

Valuation (NTM)

Forward PE 22.25

Forward PEG 1.48

Price Target $77.50

Cash Flow

FCF Yield 3.6%

SBC Adj. FCF Yield 3.1%

SBC Impact -13.6%

Margins

Gross Margin 12.4%

Operating Margin 3.1%

FCF Margin 2.8%

Growth (CAGR)

Revenue 3Y | 5Y 20.8% | 18.9%

Dil EPS 3Y | 5Y 500.0% | 42.3%

FCF 3Y | 5Y 92.8% | 9.2%

Returns

ROA 4.9%

ROE 15.2%

ROIC 8.9%

Financial Health

Net Cash

$312.05M

Current Ratio 1.59

Interest Coverage 3.14

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

BrightSpring Health Services, Inc. operates across the United States, offering a range of healthcare solutions directly within patients' homes and local communities. The company's extensive platform f...

Sector Healthcare

Industry Medical - Healthcare Information Services

Employees 23,500

IPO Date Jan 25, 2024

Website www.brightspringhealth.com

Fiscal Year January - December

Full Company Profile

Latest News

4 days ago · zacks.com

BTSG Faces $200M IRA Hit but Efficiency May Protect Profitability

BTSG faces a $200M 2026 IRA revenue headwind in Home Pharmacy, but efficiency gains and technology are helping protect profitability.

5 days ago · seekingalpha.com

BrightSpring Health Services, Inc. (BTSG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

6 days ago · zacks.com

Here's Why You Should Add BrightSpring Stock to Your Portfolio Now

BTSG's specialty pharmacy, infusion and home-based care expansion support growth, while IRA and execution risks may put pressure on near-term margins.

10 days ago · zacks.com

BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?

BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.

11 days ago · zacks.com

BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?

BrightSpring Health Services' Specialty and Infusion sales rose 30%, backed by LDD growth, new launches and expansion into rare therapies.

11 days ago · seekingalpha.com

BrightSpring Health Services: 44% Ebitda Growth Is Hard To Ignore

BrightSpring Health Services is rated buy, driven by rapid profitability growth, expanding Provider Services, and reduced financial leverage. In Q2, revenue grew 23% and adjusted EBITDA surged 44%, with management raising 2026 guidance for both revenue and EBITDA. BTSG's premium 34.38x FY1 P/E is justified by strong EBITDA growth and a forward PEG of 0.73x, with multiples declining to 22.19x by FY3.

17 days ago · zacks.com

Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?

BrightSpring Health Services is gaining acute infusion share with 20%+ volume growth, targeting 12-15 new states in a $20 billion market.

19 days ago · defenseworld.net

BrightSpring Health Services, Inc. (NASDAQ:BTSG) Receives Consensus Rating of “Buy” from Brokerages

Shares of BrightSpring Health Services, Inc. (NASDAQ: BTSG - Get Free Report) have been assigned an average recommendation of "Buy" from the twenty research firms that are covering the company, Marketbeat.com reports. Eighteen equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The